| Excerpt | Reference |
|---|
| "Insomnia is common in the elderly population." | ( Monane, M, 1992) |
| "Insomnia is commonly encountered in general medical practice, but little is known about how primary care physicians manage this problem." | ( Bauwens, SF; Shorr, RI, 1992) |
| "The risk of rebound insomnia is greater with the short half-life as compared with the long half-life benzodiazepines." | ( Gillin, JC; Johnson, LC; Spinweber, CL, 1989) |
| "Insomnia is a disorder of initiation and maintenance of sleep that results in daytime somnolence." | ( Pagel, JF, 1987) |
| "Rebound insomnia is one of the medical effects of reduction in dosage or discontinuation of neuroleptic drugs." | ( van Sweden, B, 1987) |
| "Occasional bouts of sleeplessness are normal, but for some persons, perhaps as much as 20% of the adult population, insomnia is a recurring problem for which they may turn to over-the-counter or prescription sleeping pills as a solution." | ( Fletcher, DJ, 1986) |
| "Insomnia is defined and described with special attention to differentiating the subjective complaint and the laboratory assessment of objective sleep parameters." | ( Dement, WC, 1983) |
| "Subjective insomnia is more prevalent in elderly than in young populations." | ( Curless, R; French, JM; James, OF; Wynne, HA, 1993) |
| "Primary insomnia is a persistent and recurrent disorder as well as a risk factor for depression." | ( Buysse, DJ; Dew, MA; Kupfer, DJ; Nowell, PD; Reynolds, CF, 1999) |
| "Insomnia is a prevalent health complaint in older adults." | ( Brink, D; Colecchi, C; Morin, CM; Sood, R; Stone, J, 1999) |
| "When insomnia is treated appropriately, compared with no treatment, patients' feelings about their quality of life are improved and, furthermore, do not appear to differ significantly from perceptions of quality of life in those without sleep-related problems." | ( Leger, D; Philip, P; Quera-Salva, MA, 1996) |
| "Insomnia is a particularly frequent complaint, and it is reported by more than 90% of depressed patients." | ( Thase, ME, 1999) |
| "Insomnia is associated with marked impairment in quality of life and ability to function effectively." | ( Kupfer, DJ, 1999) |
| "Insomnia is a frequent complaint in the elderly population." | ( Emilien, G; Farr, I; Hedner, J; Salinas, E; Yaeche, R, 2000) |
| "Altitude induced insomnia is a very common symptom in mountaineering." | ( Moser, B; Röggla, G; Röggla, M; Wagner, A, 2000) |
| "Insomnia is the subjective complaint of poor sleep or an inadequate amount of sleep that adversely affects daily functioning." | ( Augustin, SG; Strom, JG; Weitzel, KW; Wickman, JM, 2000) |
| "Insomnia is common among the primary care patient population, 1." | ( Lader, MH, 2001) |
| "Insomnia is a cardinal symptom for many psychiatric disorders, especially depressive disorders." | ( McCall, WV, 2001) |
| "Insomnia is a highly prevalent sleep problem that often results in poor daily functioning of the affected patient." | ( Doghramji, PP, 2001) |
| "We conclude that insomnia is associated with an overall increase of ACTH and cortisol secretion, which, however, retains a normal circadian pattern." | ( Bixler, EO; Chrousos, GP; Kales, A; Lin, HM; Mastorakos, G; Prolo, P; Vela-Bueno, A; Vgontzas, AN, 2001) |
| "Assuming that rebound insomnia is part of a withdrawal reaction, this study indicates that the risks of tolerance and dependency are low when administering zopiclone or zolpidem at the recommended doses." | ( Backhaus, J; Berger, M; Feige, B; Hohagen, F; Hornyak, M; Riemann, D; Voderholzer, U, 2001) |
| "Insomnia is the most frequently reported sleep symptom, severely affecting up to 15% of the US population." | ( Kramer, JA; Richardson, GS; Roth, T, 2002) |
| "Transient and chronic insomnia are common problems that should be clinically evaluated and appropriately treated." | ( Israel, AG; Kramer, JA, 2002) |
| "We conclude that chronic insomnia is associated with a shift of IL-6 and TNF secretion from nighttime to daytime, which may explain the daytime fatigue and performance decrements associated with this disorder." | ( Bixler, EO; Chrousos, GP; Kales, A; Lin, HM; Papanicolaou, DA; Prolo, P; Vela-Bueno, A; Vgontzas, AN; Zoumakis, M, 2002) |
| "Insomnia is a complaint of perceived poor sleep quality resulting in impairment of daytime function." | ( Grunstein, R, 2002) |
| "Patients with insomnia are characterised by excessive arousal and an inability to sleep despite reported reduced sleep hours and poor sleep quality." | ( Grunstein, R, 2002) |
| "We conclude that insomnia is a common complaint after ischemic stroke." | ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| "Insomnia is a frequent health problem in prison, but little is known about its severity and duration." | ( Elger, BS, 2003) |
| "Insomnia is a multifactorial health concern that currently affects at least 1 in 3 cancer patients, and yet most insomnia sufferers do not consult their physician regarding pharmaceutical options for relief." | ( Block, KI; Gyllenhaal, C; Mead, MN, 2004) |
| "Insomnia is a prevalent disorder, altering night time sleep, daytime mood and performance." | ( Zhdanova, IV, 2004) |
| "Chronic sleep-onset insomnia is a prevalent health complaint in adults." | ( Jacobs, GD; Otto, MW; Pace-Schott, EF; Stickgold, R, 2004) |
| "Whether insomnia is a precursor, symptom, residual symptom, or side effect of depression or its treatment, clinicians must give serious attention to and attempt to resolve sleep disturbances because of the risk of depression onset, worsening of depressive symptoms, and relapse of depression after response to antidepressant treatment." | ( Fava, M, 2004) |
| "Insomnia is a common problem that increases with age and can last months to years." | ( Ancoli-Israel, S; Hall, P; Jenkins, L; Jones, WS; Mangano, RM; Richardson, GS, 2005) |
| "Insomnia is particularly challenging for clinicians because of the lack of guidelines and the small number of studies conducted in patient populations with behavioral and pharmacologic therapies." | ( Benca, RM, 2005) |
| "Insomnia is a heterogeneous, highly prevalent condition that is associated with a high level of psychiatric, physical, social and economic morbidity." | ( Barbera, J; Shapiro, C, 2005) |
| "Chronic insomnia is a common complaint in modern society, and it is still controversial whether insomniacs share specific personality traits." | ( de Saint Hilaire, Z; Pelissolo, A; Straub, J, 2005) |
| "Insomnia is a common symptom in schizophrenia, although it is seldom the predominant complaint." | ( Monti, D; Monti, JM, 2005) |
| "Insomnia is a prevalent health complaint associated with daytime impairments, reduced quality of life, and increased health-care costs." | ( Bastien, C; Koetter, U; Morin, CM; Ware, JC; Wooten, V, 2005) |
| "Insomnia is a prevalent problem in late life." | ( Gammack, JK; Kamel, NS, 2006) |
| "Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences." | ( Bjorvatn, B; Havik, OE; Kvale, G; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B, 2006) |
| "Primary insomnia is associated with a diminished sleep-related consolidation of declarative memory." | ( Backhaus, J; Born, J; Faasch, F; Hohagen, F; Hohaus, K; Junghanns, K, 2006) |
| "Insomnia is one of the most common complaints faced in clinical practice." | ( Bellon, A, 2006) |
| "Insomnia is a common sleep disorder with a significant potential for deleterious effects on activities of daily living, productivity, and overall quality of life." | ( Borja, NL; Daniel, KL, 2006) |
| "Insomnia is a common and disabling complaint for which there is a need for improved treatments." | ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2007) |
| "However, if insomnia is severe or long-lasting, a thorough evaluation to uncover coexisting medical, neurologic, or psychiatric illness is warranted." | ( Ramakrishnan, K; Scheid, DC, 2007) |
| "Insomnia is a highly prevalent and debilitating sleep disorder, which may present with one or more of the following symptoms: difficulty initiating sleep, difficulty maintaining sleep, or waking too early without being able to return to sleep." | ( Calamaro, C, 2008) |
| "Insomnia is a highly prevalent condition that is associated with significant morbidity." | ( Zammit, G, 2008) |
| "Insomnia is an under-recognized condition." | ( Zammit, G, 2008) |
| "Sleep onset insomnia is associated with a delayed temperature rhythm presumably, at least partly, because sleep is attempted during a delayed evening wake maintenance zone." | ( Gradisar, M; Lack, LC; Lushington, K; Van Someren, EJ; Wright, HR, 2008) |
| "Insomnia is a major problem which decreases life quality." | ( Nordio, M; Romanelli, F, 2008) |
| "Insomnia is common and can result in significant distress and impaired daytime functioning." | ( Gillam, T, 2009) |
| "Insomnia is the most common sleep condition." | ( Abreu-Gonzalez, P; Henry, M; Morera, AL, 2009) |
| "Insomnia is defined as the complaint of not being able to fall asleep or to maintain sleep, and/or nonrestorative sleep, accompanied by impaired daytime functioning on a social, emotional or professional level." | ( Berger, M; Kloepfer, C; Riemann, D, 2009) |
| "Given that insomnia is a common sleep disorder that disrupts the ability to initiate and maintain restorative sleep, a better understanding of its molecular underpinning may provide crucial insights into sleep regulatory processes." | ( Donlea, J; Duntley, SP; Gimbel, SI; Gottschalk, L; Seugnet, L; Shaw, PJ; Suzuki, Y; Thimgan, M, 2009) |
| "Insomnia is a common and underdiagnosed condition that can result in significant economic and clinical consequences." | ( Morin, AK; Willett, K, 2009) |
| "Pediatric insomnia is common in children and adolescents, particularly in children who have comorbid medical, psychiatric, and neurodevelopmental disorders, and may be associated with cognitive, emotional, and psychosocial impairments that often result in significant caregiver burden." | ( Moturi, S; Owens, JA, 2009) |
| "Pediatric insomnia is prevalent in children with ADHD and impacts academic performance, social functioning, overall health, and family life." | ( Bendz, LM; Scates, AC, 2010) |
| "Symptoms of insomnia are observed during nicotine consumption and its withdrawal." | ( Andreas, S; Cohrs, S; Feige, B; Hornyak, M; Jähne, A; Kloepfer, C; Loessl, B; Riemann, D; Rodenbeck, A, 2010) |
| "Insomnia is the predominant sleep concern in children with autistic spectrum disorder (ASD), and its nature is most likely multifactorial, with neurochemical (abnormalities in serotonergic transmission or melatonin levels), psychiatric (anxiety), and behavioral (poor sleep habits) etiological factors involved." | ( Ferri, R; Miano, S, 2010) |
| "Insomnia is a common condition that affects one's ability to sleep comfortably and consequently to work effectively." | ( Dang, A; Garg, A; Rataboli, PV, 2011) |
| "Insomnia is a significant clinical problem in children treated by child psychiatrists for a variety of behavioral, neurodevelopmental, and psychiatric conditions." | ( Kirchner, HL; Mindell, JA; Owens, JA; Rosen, CL, 2010) |
| "Insomnia is a serious clinical and social problems." | ( Florkowski, A; Gałecki, P; Talarowska, M, 2010) |
| "Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients." | ( Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB, 2010) |
| "Insomnia is a severe symptom of alcohol withdrawal; however, the underlying neuronal mechanism is yet unknown." | ( Engemann, S; Sahota, P; Sharma, R; Thakkar, MM, 2010) |
| "Insomnia is a commonly reported clinical problem with as many as 50% of older adults reporting difficulty in falling and/or remaining asleep." | ( Anderson, GD; Barsness, S; Elmer, GW; Howald, WN; Kalhorn, TF; Kantor, E; Landis, CA; Taibi, DM; Vitiello, MV, 2010) |
| "Insomnia is also a major complaint among patients suffering from depressive disorders and is often aggravated by conventional antidepressants especially the specific serotonin reuptake inhibitors." | ( Brown, GM; Brzezinski, A; Cardinali, DP; Pandi-Perumal, SR; Spence, DW; Srinivasan, V, 2011) |
| "Insomnia is a prevalent disorder with nearly 50% of the US adult population reporting insomnia symptoms during the past year and 10 - 15% reporting chronic insomnia." | ( Lankford, DA, 2011) |
| "Insomnia is a common sleep disorder frequently occurring in chronic alcoholic patients." | ( Borovecki, F; Muck-Seler, D; Mustapic, M; Nedic, G; Nenadic Sviglin, K; Nikolac, M; Pivac, N, 2011) |
| "Insomnia is a frequent climacteric symptom." | ( Martinez, D; Silva, BH; Wender, MC, 2011) |
| "Insomnia is evident in the majority of youth with depression, and is associated with poorer outcomes." | ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012) |
| "Insomnia is a very frequent complaint that periodically or permanently affects up to 60% of the general population." | ( Danjou, P; Luthringer, R; Staner, L, 2012) |
| "Insomnia is a common disorder that can be comorbid with other physical and psychological illnesses." | ( Ball, RG; Bednar, RA; Bogusky, MJ; Breslin, MJ; Cabalu, TD; Coleman, PJ; Cox, CD; Cui, D; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Harrell, CM; Hartman, GD; Lemaire, W; McGaughey, GB; Prueksaritanont, T; Reiss, DR; Renger, JJ; Schreier, JD; Stellabott, J; Stevens, J; Tannenbaum, PL; Whitman, DB; Winrow, CJ; Young, SD, 2012) |
| "Insomnia is closely related to major depressive disorder (MDD) both cross-sectionally and longitudinally, and as such, offers potential opportunities to refine our understanding of the neurobiology of both sleep and mood disorders." | ( Jensen, JE; Plante, DT; Schoerning, L; Winkelman, JW, 2012) |
| "While insomnia is a well-established risk factor for the initial onset, recurrence or relapse of affective disorders, the specific characteristics of insomnia that confer risk remain unclear." | ( Bi, W; Buysse, DJ; Germain, A; Hasler, BP; James, JA; Krafty, RT; Kupfer, DJ; Nofzinger, EA; Rothenberger, SD, 2012) |
| "Insomnia is a common phenomenon particularly in patients with epilepsy." | ( Bazil, CW; Cole, J; Dave, J; Drake, E; Stalvey, J, 2012) |
| "Insomnia is common among the elderly." | ( Lemoine, P; Zisapel, N, 2012) |
| "Furthermore, insomnia is often associated with psychiatric comorbidities, and some patients with posttraumatic disruption of their circadian rhythm may be misdiagnosed as insomnia patients." | ( Baumann, CR, 2012) |
| "Insomnia is common among elderly people and nearly 30 to 40% of the adult population also suffer from insomnia." | ( Brown, GM; Brzezinski, A; Othaman, Z; Prasad, A; Srinivasan, V; Zakaria, R, 2012) |
| "Insomnia is a pervasive disorder characterized by difficulties in initiating or maintaining or non-refreshing (poor quality) sleep and clinically significant daytime distress." | ( Zisapel, N, 2012) |
| "Insomnia is prevalent in pediatrics, particularly in those with neurodevelopmental disorders." | ( Malow, BA; Robinson, AA, 2013) |
| "Insomnia is a serious medical and social problem, its prevalence in the general population ranges from 9 to 35% depending on the country and assessment method." | ( Czajkowska, B; Krzystanek, M; Lapray, D; Markowski, G; Pałasz, A; Peyron, C; Rojczyk-Gołębiewska, E; Skowronek, R; Wiaderkiewicz, R, 2014) |
| "Insomnia is a prominent modern disease that affects an increasing population." | ( Chan, YC; Chang, SS; Chen, CY; Chen, HY, 2014) |
| "Insomnia is associated with impaired quality of life." | ( Acciavatti, T; Cinosi, E; Cornelio, M; De Risio, L; Dezi, S; Di Giannantonio, M; Di Iorio, G; Marini, S; Martinotti, G; Vellante, F, 2013) |
| "Pediatric insomnia is an extrinsic sleep disorder subdivided into two categories: behavioral insomnia and insomnia related to medical, neurological, and psychiatric diseases." | ( Miano, S; Peraita-Adrados, R, 2014) |
| "Insomnia is among the most prevalent and costly of all sleep-related disorders." | ( Chang, C; Chen, MC; Glover, GH; Gotlib, IH, 2014) |
| "Insomnia is a distressing and often persisting consequence of cancer." | ( Daniels, NP; Garland, SN; Heckler, CE; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Savard, J; Shayne, M, 2015) |
| "Insomnia is frequent in schizophrenia and may contribute to cognitive impairment as well as overuse of weight inducing sedative antipsychotics." | ( DeGeorge, PC; Guloksuz, S; Krystal, AD; Palmese, LB; Reutenauer, EL; Srihari, VH; Tek, C, 2014) |
| "Insomnia is an important adverse event of mechanical thromboprophylaxis." | ( Barra, M; Caldeira, D; Costa, J; de Abreu, D; Ferreira, JJ; Santos, AT, 2015) |
| "Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and economic impacts." | ( Beaulieu-Bonneau, S; Buysse, DJ; Edinger, JD; Ivers, H; Krystal, AD; Morin, CM, 2016) |
| "Insomnia is reported in up to a quarter of healthy children and in three-quarters of children with neurodevelopmental and psychiatric conditions, resulting in negative consequences." | ( Goldman, RD; Janjua, I, 2016) |
| "Insomnia is a common feature of both medical and psychiatric disorders." | ( Krystal, AD; Sorscher, AJ, 2016) |
| "CONCLUSIONS : Insomnia is commonly comorbid with CLBP in older adults and should be routinely evaluated and treated because it is an important contributor to pain and disability." | ( Bramoweth, AD; Buysse, DJ; Gentili, A; Germain, A; Kochersberger, G; Renqvist, JG; Rodriguez, E; Rossi, MI; Weiner, DK, 2016) |
| "Chronic insomnia is one of the most prevalent central nervous system disorders." | ( Baglioni, C; Feige, B; Hennig, J; Lange, T; Nissen, C; Regen, W; Riemann, D; Spiegelhalder, K, 2016) |
| "Chronic insomnia is a common condition that affects people worldwide and has negative effects on patients' health and wellbeing." | ( Attarian, H; Kay-Stacey, M, 2016) |
| "Insomnia is becoming increasingly prevalent in the world general population." | ( Al-Dhubiab, BE, 2016) |
| "Primary insomnia is a persistent and recurrent disorder as well as a risk factor for depression." | ( Liu, Y; Mao, HJ; Song, MF; Tang, GZ; Wang, SD; Xu, XH; Yin, Y; Yu, ZH, 2017) |
| "Cancer-related insomnia is associated with diminished quality of life (QOL), suggesting that improvement in insomnia may improve QOL in cancer survivors." | ( Garland, SN; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Peoples, AR; Peppone, LJ; Perlis, ML; Roscoe, JA; Ryan, JL; Savard, J, 2017) |
| "Primary insomnia disorder is the most frequently diagnosed, sleep-related disorder." | ( Huang, HT; Lin, CH; Lin, SL; Tzeng, DS, 2017) |
| "Insomnia is a common sleep disorder that affects many adults either transiently or chronically." | ( Cho, JH; Jung, IC; Kim, AR; Kim, BK; Kim, HJ; Kim, JE; Kim, JH; Kim, MK; Kim, SP; Kwon, OJ; Park, HJ; Seo, BN, 2017) |
| "Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non-restorative sleep." | ( Coleman, PJ; Fox, SV; Gotter, AL; Hodgson, R; Ramirez, AD; Renger, JJ; Roecker, AJ; Smith, SM; Uslaner, JM; Winrow, CJ; Yao, L, 2017) |
| "In our population, insomnia is common after lung transplantation, with prevalence greater than the general population." | ( Benca, R; Brokhof, MM; Cornwell, R; Dopp, JM; Francois, ML; Hawes, DS; Hayney, MS; Katers, KM; Menninga, NJ; Radford, KL; Rohde, KA; Schlei, ZW; Weber, AK, 2017) |
| "Insomnia is prevalent among alcohol-dependent patients." | ( Lehert, P; Perney, P, 2018) |
| "Chronic insomnia is highly prevalent and associated with significant morbidity (i." | ( Abelson, JL; Faghih, RT; Morales, KH; Perlis, ML; Vargas, I; Vgontzas, AN, 2018) |
| "Insomnia disorder is a subjective condition of unsatisfactory sleep (e." | ( Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S, 2018) |
| "Insomnia is a common feature of schizophrenia." | ( Coroa, M; Madeira, N; Oliveira, P, 2019) |
| "Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries." | ( Englbrecht, C; Hajak, G; Rösner, S; Soyka, M; Wehrle, R, 2018) |
| "Insomnia is a frequent symptom in depressed patients." | ( D'Elia, A; Ferini-Strambi, L; Izzi, F; Liguori, C; Manfredi, N; Mari, L; Mercuri, NB; Placidi, F, 2019) |
| "Insomnia is the most common sleep disorder." | ( Aghaei, A; Forouzanfar, F; Rakhshandeh, H; Vahedi, MM, 2020) |
| "Insomnia is an important clinical problem affecting the elderly." | ( Albrecht, JS; Scharf, SM; Tom, SE; Vadlamani, A; Wickwire, EM, 2019) |
| "Insomnia is common in patients with major depressive disorder." | ( Brooks, S; de Boer, P; Drevets, W; Jacobs, GE; Kent, JM; Kezic, I; Luthringer, R; van Amerongen, G; van der Ark, P; van Gerven, JM; Van Nueten, L; Zuiker, R, 2019) |
| "Insomnia is a prominent complaint in patients with alcohol use disorders (AUD)." | ( Benedict, J; Ehlers, CL; Sanchez-Alavez, M; Wills, DN, 2019) |
| "Chronic insomnia is associated with poor asthma control." | ( Buysse, DJ; Luyster, FS; Ritterband, LM; Sereika, SM; Shi, X; Strollo, PJ; Wenzel, SE, 2019) |
| "Insomnia is one such condition whose prevalence is rising all over the world." | ( Bajaj, A; Bajaj, V; Kalra, I; Kumar, R; Sharma, D, 2019) |
| "Climacteric insomnia is a common symptom in climacteric women, which can seriously affect the physical and mental health of patients." | ( Du, W; He, L; Kuang, X; Xu, HW, 2019) |
| "Insomnia is a prevalent disorder that affects over one-third of the U." | ( Moniri, NH, 2019) |
| "Insomnia is one of the most common symptoms of mental pathology (affective, anxious, hypochondriac, asthenic, psychotic) and reveals a number of characteristic features depending on the structure of the mental disorder." | ( Petelin, DS; Poluektov, MG; Volel, BA, 2019) |
| "Insomnia is one of the most common minor ailments to which patients seek advice in a community pharmacy setting." | ( Elayeh, E; Hammad, EA; Tubeileh, R; Wazaify, M, 2019) |
| "Insomnia disorder is prevalent and associated with health risks in older adults; however, efficacy and safety issues with existing treatments create significant unmet needs in this patient population." | ( Dhadda, S; Filippov, G; Kumar, D; LoPresti, A; Mayleben, D; Moline, M; Murphy, P; Rosenberg, R; Zammit, G, 2019) |
| "Insomnia is a common health problem in modern societies." | ( Cen, S; Chen, W; Duan, H; Feng, S; Han, X; Tian, F; Xue, Y; Yu, L; Zhai, Q; Zhang, H; Zhao, J, 2020) |
| "Pediatric insomnia is a widespread problem and especially difficult to manage in children with neurodevelopmental disorders." | ( Kothare, SV; Pavkovic, I; Shah, YD; Stringel, V, 2020) |
| "Insomnia is a common sleep disorder that affects many adults either transiently or chronically." | ( Aldemir, R; Bolattürk, ÖF; İsmailoğullari, S; Tokmakçi, M; Ulusoy, EK, 2020) |
| "Insomnia is the most prevalent sleep disorder in the general population, and one of the most frequent reasons for consultation in the Sleep Units." | ( Abenza-Abildúa, MJ; Andreu-Vazquez, C; Suárez-Gisbert, E; Thuissard-Vasallo, IJ, 2020) |
| "Primary insomnia is a worldwide problem and it has a considerable negative impact on one's physical and mental health." | ( Chen, W; Fan, J; Guo, B; Hui, P; Liu, Y; Ma, W; Su, X; Wang, J; Wang, X; Xie, Y; Yang, J; Zhang, S; Zhao, L; Zhao, Y; Zheng, N; Zhou, L, 2021) |
| "Insomnia is a global disease with a high incidence and acupuncture therapy is a well appropriate method to treat insomnia." | ( Chen, X; Cheng, C; Deng, D; Du, L; Du, Z; Li, N; Qiao, L; Song, X; Wu, P; Yang, L; Zhou, P; Zhu, Y; Zou, T, 2020) |
| "Chronic insomnia is the most common sleep disorder in the elderly population." | ( Chiariello, A; Conte, M; Franceschi, C; Martucci, M; Miele, F; Ostan, R; Provini, F; Salvioli, S; Santoro, A, 2020) |
| "Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation." | ( Arnold, JC; Bartlett, DJ; D'Rozario, AL; Gordon, CJ; Grunstein, RR; Hoyos, CM; Irwin, C; Marshall, NS; McGregor, IS; Suraev, A; Vandrey, R; Wong, K; Yee, BJ, 2020) |
| "Insomnia is a well-established risk factor for late-life depression, yet the intermediary mechanisms are not known." | ( Boyle, CC; Cho, JH; Eisenberger, NI; Irwin, MR; Olmstead, RE; Piber, D; Sadeghi, N; Tazhibi, M, 2020) |
| "Insomnia is a common medical complaint." | ( Jones, KR; Orr, WC; Raad, S; Wilkerson, M, 2020) |
| "Insomnia is less prevalent and less severe in PWE treated with perampanel independent of depressive symptoms, which will be helpful for treating PWE and comorbid sleep disturbances." | ( Jo, S; Jung, M; Kim, HJ; Kim, HW; Kim, SJ; Koo, YS; Lee, SA, 2020) |
| "Insomnia is an economic burden and public health problem." | ( Deng, N; Liu, T; Ren, X; Wang, G; Wang, Q; Yan, D; Zhang, X, 2021) |
| "Insomnia is a global health problem among university students which is associated with various psychiatric problems like depression and anxiety." | ( Azad, F; Chowdhury, AI; Ghosh, S; Hasan, MF; Khandakar, KAS, 2020) |
| "Insomnia disorder is a common sleep disorder and frequently emerges in the context of menopause, being associated with menopause-specific factors such as hot flashes and other psychosocial variables." | ( Baker, FC; Colrain, IM; de Zambotti, M; Schulte, T; Sugarbaker, D; Yuksel, D, 2021) |
| "Insomnia is a complex sleep disorder that compromises quality of life and affects approximately 10% of the general population." | ( Krystal, A; Zammit, G, 2021) |
| "Insomnia is a sleep disorder in which people have trouble falling asleep or staying asleep, or both." | ( Bsharat, M; Cheng, JY; Filippov, G; Hall, N; Moline, M; Zammit, GK, 2021) |
| "Insomnia is one of the most common sleep disorders and is difficult to completely treat because of the undesirable side effects of hypnotics." | ( Bang, SK; Choi, KH; Kang, SY; Kwon, OS; Moon, JY; Ryu, Y; Seo, SY, 2021) |
| "Insomnia is one of the most prevalent sleep disorders, which imparts tremendous societal and economic impact." | ( Chen, CR; Huang, ZL; Jiang, S; Qu, WM; Zhang, W; Zhong, YH, 2022) |
| "Occasional sleeplessness is poorly understood, has a significant impact on quality of life in children and their families, and is often challenging to manage." | ( Bongiorno, PB; Goldman, RD; Olcese, JM; Shatkin, JP; Witt-Enderby, PA, 2021) |
| "Insomnia is a sleep disorder characterized by difficulty of falling asleep or maintaining sleep, which affects different age groups." | ( Alves, IA; Bandeira, VAC; Bueno, APR; Savi, FM, 2021) |
| "Insomnia is a pervasive sleep disorder affecting numerous patients across diverse demographical populations and comorbid disease states." | ( Bliwise, DL; Roland, JP, 2021) |
| "Insomnia is a prevalent condition that presents itself at both the symptom and diagnostic levels." | ( Frey, BN; Kuhathasan, N; MacKillop, J; Minuzzi, L, 2021) |
| "Although insomnia is by far the most common sleep disorder, our understanding of its neurobiology is limited." | ( Basta, M; Bixler, EO; Chrousos, GP; Fernandez-Mendoza, J; Lenker, KP; Vgontzas, AN, 2022) |
| "Insomnia is common in people with long-term medical conditions and is related to increased mortality and morbidity." | ( Boss, HM; Braamse, AMJ; Knoop, H; Pot, I; Rauwerda, NL; Rikkert, ME; Timmerhuis, TPJ; van Straten, A; Zondervan, A, 2021) |
| "Insomnia is highly prevalent in patients with type 2 diabetes mellitus (T2DM)." | ( Ge, Q; Liu, Z; Xiong, S; Yao, N; Zhang, X, 2022) |
| "Insomnia is a highly prevalent disorder and a state of 24 h hyperarousal is considered as a key factor of this condition." | ( Benz, F; Dressle, RJ; Feige, B; Mey, NC; Riemann, D; Schmucker, C; Spiegelhalder, K, 2022) |
| "Insomnia is a symptom of delirium." | ( Hirayama, T; Matsuoka, H; Nakahara, R; Sadahiro, R; Terada, T; Wada, S, 2022) |
| "Insomnia is likely related to genetic susceptibility and a triggering event, leading to hyper-arousal states and functional brain disturbances." | ( Berger, AA; Gilbert, E; Hasoon, J; Kaye, AD; Keefe, J; Sottosanti, ER; Thase, ME; Urits, I; Viswanath, O; Winnick, A, 2022) |
| "Insomnia is a frequent complaint of patients with Parkinson's disease, and it negatively affects quality of life." | ( Abril, B; Aerts, C; Anheim, M; Arnulf, I; Benard-Serre, N; Castelnovo, G; Corbillé, AG; De Cock, VC; Devos, D; Dodet, P; Doulazmi, M; Drapier, S; Eusebio, A; Fantini, ML; Lacombe, S; Lambert, I; Lebouteux, M; Leclair-Visonneau, L; Leu-Semenescu, S; Marques, A; Monaca, C; Olivet, H; Roze, E; Ruppert, E; Sallansonnet-Froment, M; Vidailhet, M; Vitello, N, 2022) |
| "Insomnia is a chronic disorder with a mean prevalence ranged from 6% to 15% worldwide." | ( Callede, N; Casettari, L; Goole, J; Loosveldt, N; Masciotti, T, 2022) |
| "Cancer-related insomnia is a highly prevalent complaint in cancer patients." | ( Huang, S; Huang, Y; Lao, L; Qiu, X; Zhang, J; Zhang, Z; Zhang, ZJ, 2022) |
| "Symptoms of insomnia are associated with alcohol-related harm, but may buffer associations between drinking and acute physiological consequences of alcohol." | ( Boness, CL; DiBello, AM; Froeliger, B; Miller, MB, 2022) |
| "Chronic insomnia is the long-term inability to fall asleep easily or to stay asleep." | ( El-Moustaid, F; Forma, F; Pratiwadi, R; Smith, N; Thorndike, F; Velez, F, 2022) |
| "Insomnia is a common sleep disorder associated with poor health outcomes." | ( Cropsey, KL; Gamble, KL; Hawes, ES; Mildrum Chana, S; Palenski, PE; Thomas, SJ; Wolford-Clevenger, C, 2023) |
| "Insomnia is the most frequent sleep disorder worldwide and is a prominent risk factor for mental and physical health deterioration." | ( Li, JC; Li, S; Li, Y; Wang, LX; Xue, R; Yu, JJ; Zhang, Y; Zhang, YZ; Zhao, Q, 2023) |
| "Insomnia is frequent in patients with advanced cancer, and a variety of pharmacological agents is used to treat this condition." | ( Hjermstad, MJ; Jakobsen, G; Kaasa, S; Klepstad, P; Paulsen, Ø; Sjue, K, 2022) |
| "Insomnia is a common condition that may be caused by or coexist with other medical or psychological illnesses." | ( Ahmed, SH; Asghar, MS; Habiba, U; Shaikh, TG; Waseem, R; Waseem, S, 2023) |
| "Insomnia is a well-recognized clinical sleep disorder in the adult population." | ( Liu, C; Qin, S; Wang, X; Wu, W; Xi, H, 2023) |
| "Insomnia is associated with insulin resistance (IR) in observational studies; however, whether insomnia is causally associated with IR remains unestablished." | ( Ai, S; Cui, R; Feng, H; Guo, S; He, L; Li, G; Liang, Y; Sun, Y; Tan, X; Wang, X; Xu, Y; Yang, L; Zhang, J; Zhao, C; Zhao, G, 2023) |
| "Chronic insomnia disorder is one of the most common problems in postmenopausal women, exacerbated by underdiagnosis and improper treatment." | ( Sophonsritsuk, A; Thongchumnum, W; Vallibhakara, O; Vallibhakara, SA, 2023) |
| "Insomnia is highly prevalent in modern society." | ( Chen, PY; Chiu, HY; Hasan, F; Lee, HC; Romadlon, DS; Tu, YK; Wang, YH; Yuliana, LT, 2023) |
| "Insomnia is the most common sleep disorder and is often comorbid with mental and physical diseases." | ( Peng, Q; Tang, L; Zhang, F; Zhang, X, 2023) |
| "Insomnia is one of the most prevalent sleep disorders characterized by an inability to fall or stay asleep." | ( Alavi, N; Jagayat, J; Kumar, A; Moghimi, E; Nikjoo, N; Omrani, M; Patel, C; Shirazi, A; Stephenson, C; Zhu, Y, 2023) |
| "Insomnia is common in midlife women." | ( Cheng, JY; Inabe, K; Malhotra, M; Moline, M; Nishida, M; Pappadopulos, E; Pinner, K; Terauchi, M; Yardley, J, 2023) |
| "Insomnia is a common sleep disorder around the world, which is harmful to people's health, daily life, and work." | ( Cai, X; Fan, P; Hu, R; Jing, L; Lu, B; Luo, J; Luo, Y; Mao, G; Mo, F; Shan, J; Song, Y; Wang, Y; Xu, W, 2023) |
| "Insomnia is a common sleep disorder without effective therapy and can affect a person's life." | ( Chen, X; Gu, Y; Han, T; Khalid, R; Wang, H, 2023) |
| "Insomnia is a common disorder and cognitive behavioural therapy for insomnia (CBT-I) is recommended as first-line treatment." | ( Benz, F; Ell, J; Schmid, SR; Spille, L, 2023) |
| "Insomnia is closely linked to anxiety and depression, and its pathogenesis is related to biology, psychology, and sociology." | ( Deng, K; Guo, D; Guo, J; Guo, Q; Li, H; Li, J; Li, T; Liu, D; Shi, Y; Sun, J; Tang, T; Wang, F; Wang, W; Wang, Y; Wu, Z; Yang, K; Yang, M; Zhang, X; Zou, J, 2024) |
| "Sleep onset insomnia is associated with later timed circadian rhythms and can be treated with morning bright light to shift rhythms to an earlier timing." | ( Lack, LC; Lovato, N; Micic, G, 2023) |
| "Insomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care." | ( Shaha, DP, 2023) |
| "Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies." | ( D'Rozario, AL; Gordon, CJ; Grunstein, RR; Hoyos, CM; Irwin, C; Lavender, I; Marshall, N; McCartney, D; McGregor, I; Saini, B; Suraev, A; Yee, B, 2023) |
| "Insomnia is a modifiable risk factor for suicide often treated with medications." | ( Gibbons, JB; Hur, K; Lavigne, JE; Pigeon, WR, 2023) |
| "Insomnia is a modifiable risk factor for suicide, yet many medications used to treat insomnia have never been tested for the indication in clinical trials." | ( Gibbons, JB; Hur, K; Lavigne, JE; Pigeon, WR, 2023) |
| "Insomnia is one of the most common sleep-related diseases." | ( Chen, XQ; Li, CL; Ma, BM; Yi, HL, 2023) |
| Excerpt | Reference |
|---|
| "Seventy insomniac patients, previously unresponsive to conventional hypnotic dosage, were treated for seven nights with temazepam in 20 mg soft gelatin capsules (Euhypnos Forte)." | ( Moon, CA; Schiller, M, 1979) |
| "Experimental sleep disturbance (model insomnia) was produced by intermittent white noise and the administration of 10 mg of methylphenidate (MPD)." | ( Honda, H; Okuma, T, 1978) |
| "Rebound insomnia followed the withdrawal of three benzodiazepine hypnotic drugs, each of which had been administered in a single nightly dose for only short-term periods." | ( Kales, A; Kales, JD; Scharf, MB, 1978) |
| "1 Hospitalized patients suffering from insomnia were treated with N-demethyldiazepam (30 mg p." | ( Alberti, GG; De Maio, D; Franciosi, P; Gomeni, R; Scieghi, G; Tognoni, G, 1975) |
| "Anxiety, insomnia and drug response however showed significant correlation with pretreatment 5-HIAA level." | ( Banki, CM, 1977) |
| "Twenty-eight patients (12 M, 16 F) with insomnia were treated with nitrazepam 5 mg/d and oxazepam 25 mg/d, each for 11 days, in a double-blind crossover comparison with placebo." | ( Berntzen, D; Götestam, KG; Oppöyen, F, 1991) |
| "An untreated insomnia group also was included." | ( Balter, MB; Uhlenhuth, EH, 1991) |
| "Forty-two insomniac female in-patients between 30 and 65 years of age were included in a double blind, parallel group trial and were randomly allocated to the two treatments." | ( Cesana, B; Frattola, L; Maggioni, M; Priore, P, 1990) |
| "Rebound insomnia, a worsening of sleep compared with pretreatment levels, has been reported upon discontinuation of short half-life benzodiazepine hypnotics." | ( Gillin, JC; Johnson, LC; Spinweber, CL, 1989) |
| "Sleep improved with all treatments." | ( Buck, L; Csima, A; Mamelak, M; Price, V, 1989) |
| "In the small number of patients with chronic insomnia who have received extended treatment with loprazolam, no evidence of tolerance has occurred, although rebound insomnia was evident 3 days after drug withdrawal in several studies." | ( Clark, BG; Dawson, GW; Jue, SG; Ward, A, 1986) |
| "In younger situational insomniacs, whose sleep problem consists solely of longer than usual sleep latencies, L-tryptophan is effective in reducing sleep onset time on the first night of administration in doses ranging from 1 to 15 g." | ( Schneider-Helmert, D; Spinweber, CL, 1986) |
| "We studied the reversibility of this insomnia in physiological slow-wave sleep (SWS) and paradoxical sleep (PS) after 5-hydroxytryptophan (5HTP) and serotonin (5HT) administration." | ( Buda, C; Janin, M; Jouvet, M; Petitjean, F; Sallanon, M, 1985) |
| "Mild rebound insomnia may occur in some patients when treatment is stopped." | ( Clissold, SP; Langley, MS, 1988) |
| "This worsening of the insomnia is consistent with the observations of sleep disturbance at the beginning of treatment with beta-blocking drugs." | ( Benoit, JF; Danjou, P; Puech, A; Warot, D, 1987) |
| "No rebound insomnia was evident during a 7 day post-treatment withdrawal period for either zopiclone or nitrazepam." | ( Anderson, AA, 1987) |
| "Thirty-nine subjects with chronic insomnia were treated with L-tryptophan (L-TRP) in a double-blind, cross-over study." | ( Bauer, J; Demisch, K; Demisch, L; Georgi, K, 1987) |
| "Three groups of ten middle-aged insomniac patients were treated with placebo, flurazepam, or zopiclone for 12 consecutive days in a study designed to compare the residual daytime effects of long-acting flurazepam and short-acting zopiclone on a variety of cognitive and motor tasks." | ( Buck, L; Csima, A; Mamelak, M; Price, V; Smiley, A, 1987) |
| "Sixty-three outpatients with chronic insomnia were treated for 3 weeks under double-blind conditions with either brotizolam (n = 29) at a dose of 0." | ( Case, WG; Chung, HR; Mauriello, R; Morris, RJ; Newman, HM; Rickels, K; Rosenfeld, H, 1986) |
| "Following 3 days treatment there was no rebound insomnia." | ( Alterwain, P; Altier, H; Debellis, J; Monti, D; Monti, JM; Pellejero, T, 1987) |
| "Fifty-nine outpatients with insomnia were treated in a 3-week study to assess the safety and efficacy of a new triazolothienodiazepine with a short t1/2, brotizolam." | ( Dominguez, RA; Goldstein, BJ; Jacobson, AF; Steinbook, RM, 1985) |
| "Sixty young male patients with insomniac disorders were treated with nitrazepam 5 mg or triazolam 0." | ( Blumenthal, M; Byring, R; Koivula, K, 1980) |
| "In a small number of patients with chronic insomnia receiving extended treatment with triazolam in a clinical setting or in some sleep laboratory studies, no evidence of tolerance occurred; however, some evidence of reduced effect with repeated administration has been reported in one sleep laboratory study." | ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1981) |
| "Experimental sleep disturbances (model insomnia) were produced by the administration of methylphenidate (MPD) 10 mg and caffeine (CAF) 150 mg." | ( Matsue, Y; Matsuoka, H; Okuma, T; Toyomura, K, 1982) |
| "Fifty-five patients complaining of insomnia entered a single-blind general practice study and were treated with either 400 mg chlormezanone or 20 mg temazepam at night for 2 weeks." | ( Van Steenis, D, 1982) |
| "Early morning insomnia, a significant increase in wakefulness during the final hours of drug nights, occurred after 1 or 2 weeks of nightly administration of benzodiazepine hypnotics with short elimination half-lives, when tolerance had begun to develop." | ( Bixler, EO; Kales, A; Kales, JD; Soldatos, CR, 1983) |
| "Forty-three outpatients with "midwinter insomnia" (an early type insomnia commonly seen north of the Polar Circle when the sun stays below the horizon) were randomly allocated to one of three treatment groups, receiving either 15 mg midazolam, 1 mg flunitrazepam, or placebo, for 5 nights, double blind, after 3 nights without drug." | ( Bratlid, T; Gordeladze, JO; Lingjaerde, O; Westby, OC, 1983) |
| "injection in PCPA pretreated insomniac cats." | ( Buda, C; Janin, M; Jouvet, M; Sallanon, M, 1982) |
| "In healthy adult insomniacs it was well tolerated upon repeated administration for 28 days." | ( Deschenes, JP; Elie, R, 1983) |
| "The diagnosis and treatment of insomnia is a major clinical issue." | ( Dement, WC, 1983) |
| "In an open study 7 patients with severe insomnia were treated by a series of 10 injections with the delta-sleep-inducing peptide (DSIP)." | ( Kaeser, HE, 1984) |
| "Of symptoms not on the checklist, insomnia was more common during treatment with zimelidine." | ( Simpson, RJ; Skegg, DC; Tiplady, B, 1980) |
| "latencies, in insomniac Cats pretreated with P-chlorophenylalanine." | ( Buda, C; Janin, M; Jouvet, M; Petitjean, F; Sallanon, M, 1980) |
| "Since insomnia was not influenced by clonidine, we offered 100 mg doxepine and/or 10 mg nitrazepam (the latter only until day 4 of treatment)." | ( Hermann, P; Presslich, O; Schanda, H, 1983) |
| "In healthy adult insomniacs it was well tolerated upon repeated administration for 28 days." | ( Deschenes, JP; Elie, R, 1982) |
| "Six middle aged subjects complaining of chronic insomnia associated with dysthymia were investigated in a 2-month single blind study: a 7-day placebo treatment period, followed by a 6-week phase with increasing doses of trazodone controlled release (CR) formulation (50 mg through days 8-10; 75 mg through days 11-13; 150 mg through days 14-49) and then a final 7-day withdrawal period under placebo." | ( Boselli, M; Di Giovanni, G; Parrino, L; Spaggiari, MC; Terzano, MG, 1994) |
| "In the PCPA-pretreated insomniac rats, PGD2 infusion resulted in an immediate increase in slow-wave sleep (SWS) and an increase with a 2-h latency in paradoxical sleep (PS)." | ( Hayaishi, O; Jouvet, M; Matsumura, H; Nakajima, T; Onoe, H; Sakai, K; Satoh, S, 1994) |
| "A recent study found that insomniacs self administer capsules at bedtime at a high rate, with triazolam (0." | ( Pedrosi, B; Roehrs, T; Rosenthal, L; Roth, T, 1996) |
| "Long-term doxepin treatment of chronic insomniac patients not only improves sleep but also restores nocturnal melatonin secretion in these patients." | ( Adler, L; Bandelow, B; Hajak, G; Herrendorf, G; Huether, G; Rodenbeck, A; Rüther, E; Staedt, J, 1996) |
| "Since homogeneous samples of insomniacs are difficult to recruit for pharmacotherapy studies, normal sleepers can be used to assess the protective effect of hypnotic drugs, under standardized nonconducive conditions." | ( Boselli, M; Parrino, L; Smerieri, A; Spaggiari, MC; Terzano, MG, 1997) |
| "Mean time to resolution of insomnia was significantly faster in adolescents treated with trazodone rather than fluoxetine (2." | ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997) |
| "Twenty-four men and women with insomnia, age 21-50 years, self administered hypnotics under a single-choice with placebo, single-choice with triazolam (0." | ( Pedrosi, B; Roehrs, T; Rosenthal, L; Roth, T; Zorick, F, 1997) |
| "In subjects with primary insomnia the administration of 20 mg oral temazepam results in changes in both the pharmacodynamic measures and in quality of sleep." | ( Breimer, DD; Cohen, AF; Danhof, M; Kamphuisen, HA; Kemp, B; Oberyé, JJ; Peck, CC; Pieters, MS; Schoemaker, RC; Tuk, B; van Gerven, J, 1997) |
| "Rates of improvement in insomnia (HAM-D insomnia items), agitation (HAM-D agitation item), and anxiety (SCL anxiety subscale) were essentially identical in the two treatment groups." | ( Grothaus, L; Heiligenstein, JH; Katon, W; Revicki, D; Simon, GE, 1998) |
| "Benzodiazepine use in the treatment of insomnia may cause benzodiazepine dependence, especially in opiate users." | ( Jarusuraisin, N; Srisurapanont, M, 1998) |
| "The severity of initial insomnia predicted only one estrogen-induced sleep improvement effect: the more the subjects experienced insomnia, the better the estrogen replacement therapy facilitated falling asleep (r = 0." | ( Erkkola, R; Helenius, H; Irjala, K; Polo, O; Polo-Kantola, P, 1998) |
| "Management of chronic insomnia with zopiclone needs a multidimensional approach involving the proper diagnosis of possible underlying causes, and combined use of causal treatment, general sleep hygiene measures, basic elements of psychological treatment and adjunctive medication." | ( Hajak, G; Rodenbeck, A, 1996) |
| "When insomnia is treated appropriately, compared with no treatment, patients' feelings about their quality of life are improved and, furthermore, do not appear to differ significantly from perceptions of quality of life in those without sleep-related problems." | ( Leger, D; Philip, P; Quera-Salva, MA, 1996) |
| "Evaluation and treatment of insomnia are frequent procedures in the physician's everyday practice, since many patients seek medical treatment for this condition." | ( Ganzoni, E; Gugger, M, 1999) |
| "Therefore, early relief of insomnia in a depressed patient, in addition to alleviating other symptoms, may increase adherence to treatment and increase daytime performance and overall functioning, while complete relief of insomnia may improve prognosis." | ( Thase, ME, 1999) |
| "The occurrence of rebound insomnia and withdrawal effects on discontinuation of treatment was also assessed." | ( Elie, R; Emilien, G; Farr, I; Rüther, E; Salinas, E, 1999) |
| "There was no evidence of rebound insomnia or withdrawal symptoms after discontinuation of 4 weeks of zaleplon treatment." | ( Elie, R; Emilien, G; Farr, I; Rüther, E; Salinas, E, 1999) |
| "There was a weak indication of rebound insomnia after discontinuation of treatment with the 10-mg dose, but no significant difference in common treatment-emergent adverse events across treatment groups." | ( Emilien, G; Farr, I; Hedner, J; Salinas, E; Yaeche, R, 2000) |
| "Rebound insomnia was not observed after sudden discontinuation of up to 12 months' treatment with zaleplon 5 and 10 mg/night and up to 4 weeks' treatment with zaleplon 20 mg/night." | ( Dooley, M; Plosker, GL, 2000) |
| "Several adverse events (insomnia, asthenia, somnolence, gastroenteritis, decreased libido, chills, and confusion) occurred significantly more frequently among fluoxetine-treated patients." | ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000) |
| "For the past 4 decades, treatment of insomnia has shifted away from the use of barbiturates toward the use of hypnotic agents of the benzodiazepine class." | ( Augustin, SG; Strom, JG; Weitzel, KW; Wickman, JM, 2000) |
| "Zolpidem 10 mg is effective in treating insomnia when used intermittently, without evidence of discontinuation effects or increased frequency of pill taking." | ( Erman, M; Jamieson, A; Randazzo, A; Roth, T; Scharf, M; Schweitzer, PK; Walsh, JK; Ware, JC, 2000) |
| "Trazodone has been used widely to treat insomnia in depressed patients." | ( Hanson, CA; Krahn, LE; Pileggi, TS; Rummans, TA, 2001) |
| "Administering low-dose trazodone for insomnia in conjunction with ECT does not appear to increase cardiovascular complications." | ( Hanson, CA; Krahn, LE; Pileggi, TS; Rummans, TA, 2001) |
| "Previous studies have shown that insomniacs self-administer hypnotics at high nightly rates." | ( Bonahoom, A; Pedrosi, B; Roehrs, T; Rosenthal, L; Roth, T, 2001) |
| "If the insomnia fails to respond, then consideration should be given to the possibility of inadequate treatment of the primary psychiatric disorder, iatrogenic insomnia, insomnia related to a medical disorder, or learned/habit insomnia." | ( McCall, WV, 2001) |
| "(1) In chronic insomnia, cognitive-behaviour treatments appear to be as effective as benzodiazepines." | ( , 2001) |
| "Sleep maintenance insomnia and the item "troubled sleep" showed a large treatment response, whereas sleep onset insomnia improved less substantially." | ( Best, SR; Lenoci, M; Lipsey, TL; Marmar, CR; Metzler, TJ; Neylan, TC; Schoenfeld, FB; Weiss, DS, 2001) |
| "No subjects reported insomnia with treatment." | ( Dinner, D; Foldvary, N; Lee, J; Morris, HH; Perry, M, 2001) |
| "Transient and chronic insomnia are common problems that should be clinically evaluated and appropriately treated." | ( Israel, AG; Kramer, JA, 2002) |
| "Previous studies have shown that insomniacs self-administer hypnotics at high nightly rates." | ( Bonahoom, A; Pedrosi, B; Roehrs, T; Roth, T; Zorick, F, 2002) |
| "This study shows that the minority of insomniacs who self-administer hypnotics during the day are physiologically aroused and the drug reduces their arousal suggesting that their daytime self-administration, like their night-time self-administration, is more consistent with therapy-seeking than drug-seeking behavior, at least for the short-term." | ( Bonahoom, A; Pedrosi, B; Roehrs, T; Roth, T; Zorick, F, 2002) |
| "In elderly insomniacs, melatonin treatment decreased sleep latency and increased sleep efficiency." | ( Brusco, LI; Cardinali, DP; Furio, AM; Pérez Lloret, S, 2002) |
| "Most patients with GAD suffer from insomnia, and treating insomnia can be of great benefit to them." | ( Culpepper, L, 2002) |
| "Cotherapy was effective in reducing insomnia but not anxiety or core symptoms (low mood, suicidality, reduced interest)." | ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2002) |
| "The impact of insomnia on daytime functioning and its relationship with medical and psychiatric illnesses necessitate early treatment to prevent insomnia becoming persistent and to avoid the development of complications." | ( Palomba, V; Parrino, L; Rossi, M; Smerieri, A; Terzano, MG, 2003) |
| "Nightmares and insomnia in combat-related post-traumatic stress disorder (PTSD) might be resistant to treatment with selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines." | ( Jakovljević, M; Mihaljević-Peles, A; Sagud, M, 2003) |
| "We assessed the preference of insomniac patients between a single dose of 10 mg zolpidem or zaleplon, respectively, administered in random order on two consecutive nights." | ( Allain, H; Bentué-Ferrer, D; Breton, SL; Gandon, JM; Polard, E, 2003) |
| "Although in some patients rebound insomnia and specific side effects must be considered, our findings give a further rationale for the use of antidepressants in the treatment of primary insomnia." | ( Cohrs, S; Hajak, G; Huether, G; Jordan, W; Rodenbeck, A; Rüther, E, 2003) |
| "For the symptomatic drug treatment of insomnias, the specific metabolic and pharmacokinetic, as well as possible interactions, should be considered." | ( Wiegand, MH, 2003) |
| "Thirty-eight insomniacs took part in a 5-week, double-blind, placebo-controlled study of the effects of 2 weeks of administration of temazepam 20 mg on sleep." | ( Nutt, DJ; Potokar, J; Rich, AS; Rich, NC; Wilson, SJ, 2004) |
| "30 subjects with primary insomnia were enrolled in this study and were randomly assigned to 1 of 3 treatment conditions: (1) placebo plus CBT, (2) 100 mg modafinil plus CBT, or (3) 100 mg modafinil plus a contact control (monitor-only condition)." | ( Enright, T; Jungquist, C; Nowakowski, S; Orff, H; Perlis, ML; Plotkin, K; Smith, MT, 2004) |
| "The perceived degree of improvement of insomnia was proportional to the advance in timing of sleep onset obtained with treatment." | ( Benedetti, F; Bernasconi, A; Colombo, C; Florita, M; Pontiggia, A; Smeraldi, E, 2004) |
| "Whether insomnia is a precursor, symptom, residual symptom, or side effect of depression or its treatment, clinicians must give serious attention to and attempt to resolve sleep disturbances because of the risk of depression onset, worsening of depressive symptoms, and relapse of depression after response to antidepressant treatment." | ( Fava, M, 2004) |
| "Many patients with chronic insomnia, including primary insomnia and insomnia secondary to a variety of medical and psychiatric disorders, also benefit from pharmacotherapy." | ( Walsh, JK, 2004) |
| "Participants with chronic insomnia (N = 53), completed 2 baseline weeks of sleep diaries, and were randomly assigned to a treatment group for 2 more weeks." | ( Anderson, T; Betz, B; Binks, PG; Carney, CE; Fuller, KH; Hurry, MJ; Johnson, J; Lajos, LE; Tucci, JM; Waters, WF, 2003) |
| "There was no evidence of tolerance or rebound insomnia after therapy discontinuation." | ( Amato, DA; Caron, J; McNabb, LJ; Roth, T; Zammit, GK, 2004) |
| "Search terms used were "insomnia," "behavioral therapy," and the generic names of agents commonly used to treat insomnia (the Food and Drug Administration-approved benzodiazepines and nonbenzodiazepines, trazodone, and over-the-counter agents)." | ( Benca, RM, 2005) |
| "The treatment of insomnia involves pharmacological and non-pharmacological interventions." | ( Barbera, J; Shapiro, C, 2005) |
| "Sleep-onset and maintenance insomnia is a characteristic feature of schizophrenic patients regardless of either their medication status (drug-naive or previously treated) or the phase of the clinical course (acute or chronic)." | ( Monti, D; Monti, JM, 2005) |
| "Six primary insomnia patients (Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)) and six normal volunteers with no sleep complaints participated in a double-blind study with caffeine or placebo administered under a cross-over design with each subject serving as his or her own control." | ( Campos, RM; Castaño, A; Salín-Pascual, RJ; Shiromani, PJ; Valencia-Flores, M, 2006) |
| "There was no evidence of significant rebound insomnia or withdrawal effects following treatment discontinuation." | ( Roth, T; Sainati, S; Seiden, D; Wang-Weigand, S; Zee, P; Zhang, J, 2006) |
| "In older adults with chronic insomnia, ramelteon significantly reduced patient reports of sleep latency over five weeks of treatment with no significant rebound insomnia or withdrawal effects." | ( Roth, T; Sainati, S; Seiden, D; Wang-Weigand, S; Zee, P; Zhang, J, 2006) |
| "This article will review the causes of insomnia in the elderly, the approach to patient evaluation, and the nonpharmacologic and pharmacologic treatment of insomnia." | ( Gammack, JK; Kamel, NS, 2006) |
| "Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events." | ( Bukstein, O; Greenhill, L; Lerner, M; McBurnett, K; McGough, JJ; Stein, M; Wilens, TE, 2006) |
| "Adults over age 55 with primary insomnia were randomly assigned to six weeks of double-blind treatment with paroxetine (N = 14) or placebo (N = 13)." | ( Buysse, DJ; Hall, M; Mazumdar, S; Miller, MD; Pollock, BG; Reynolds, CF, 2006) |
| "Patients meeting DSM-IV criteria for primary insomnia and screening polysomnography criteria (wakefulness after sleep onset [WASO] >or= 20 min and latency to persistent sleep >or= 20 min) were randomized to 2 weeks of nightly treatment with eszopiclone 2 mg (n = 136) or placebo (n = 128)." | ( Erman, M; Krystal, AD; McCall, WV; Rosenberg, R; Scharf, M; Wessel, T; Zammit, GK, 2006) |
| "Improvement in managing insomnia will result from systematic research with these drugs, with drugs in development, and with novel uses, such as co-therapy." | ( Curry, DT; Eisenstein, RD; Walsh, JK, 2006) |
| "In 2 trials of patients with primary insomnia, patients treated with ramelteon 4 to 32 mg had significant reductions in latency to persistent sleep (LPS) compared with placebo (P < 0." | ( Borja, NL; Daniel, KL, 2006) |
| "In patients with insomnia, treatment with ramelteon was generally well tolerated and resulted in modest but statistically significant decreases in LPS." | ( Borja, NL; Daniel, KL, 2006) |
| "Many options are available to treat insomnia, to assist with either falling asleep (sleep onset) or maintaining sleep." | ( Jarvis, CI; Lynch, AM; Morin, AK, 2007) |
| "The consequences of insomnia, if left untreated, may contribute to the risks of developing additional serious conditions, such as psychiatric illness, cardiovascular disease, or metabolic issues." | ( Doghramji, PP, 2007) |
| "Management of insomnia in the elderly appears to have a better outcome when pharmacotherapy is combined with SHT rather than SHT alone." | ( Aguglia, E; De Vanna, M; Onor, ML; Rubiera, M, 2007) |
| "Research indicates that insomnia may contribute significantly to healthcare costs; however, information on the effects of treatments on costs has not been thoroughly published." | ( Jhaveri, M; Pollack, M; Seal, B; Wertz, D, 2007) |
| "In elderly patients with primary insomnia characterized by sleep-maintenance difficulty, indiplon, 15 mg, was well tolerated and significantly improved all patient-reported measures of sleep during 2 weeks of treatment." | ( Farber, R; Landin, R; Lankford, DA; Lydiard, RB; Seiden, DJ; Walsh, JK, 2006) |
| "It is hard to define what ratio of insomnia and daytime hypersomnia is caused by the antiparkinsonian treatment, by the somatic and mental-emotional symptoms of the neurodegenerative disease and by the neurodegenerative brain process itself." | ( Kovács, GG; Lalit, N; Péter, H; Szucs, A, 2007) |
| "In patients with chronic insomnia, long-term nightly treatment with 10 mg and 20 mg doses of indiplon resulted in significant and sustained efficacy in sleep onset, maintenance, and duration, and significant associated improvement in both daytime functioning and quality of life." | ( Black, J; Farber, R; Hull, S; Landin, R; Scharf, MB, 2007) |
| "Patient-reported sleep measures, Insomnia Severity Index, Medical Outcomes Study Short-Form Health Survey (SF-36), Work Limitations Questionnaire, and other assessments measured during baseline, treatment Months 1-6, and 2 weeks following discontinuation of treatment." | ( Amato, DA; Caron, J; Krystal, AD; Roach, J; Roth, T; Rubens, R; Schaefer, K; Wallenstein, G; Walsh, JK; Wessel, TC, 2007) |
| "In elderly patients with primary insomnia, indiplon 5 mg and 10 mg were efficacious in inducing and maintaining sleep and improving sleep quality during the two weeks of treatment." | ( Burke, J; Farber, R; Moscovitch, A; Roth, T; Walsh, JK, 2007) |
| "Physicians may initiate treatment of insomnia at an initial visit; for patients with a clear acute stressor such as grief, no further evaluation may be indicated." | ( Ramakrishnan, K; Scheid, DC, 2007) |
| "Although not yet evaluated for transient insomnia in older adults, eszopiclone has been shown to be safe and efficacious for short-term treatment (2 weeks) of chronic, primary insomnia in older adults (64-91 years)." | ( Dautovich, ND; McCrae, CS; Ross, A; Stripling, A, 2007) |
| "The treatment of primary insomnia frequently lasts longer than four weeks, the maximal time allowed for daily hypnotics use." | ( Czasak, K; Jernajczyk, W; Musińska, I; Sobańska, A; Szatkowska, E; Wichniak, A; Wierzbicka, A, 2007) |
| "The Athens Insomnia Scale (AIS), the Sheehan Disability Scale (SDS), the Clinical Global Impression (CGI), the Leeds Sleep Questionnaire (LSEQ) were completed before (Day 0) and after each month of treatment (Day 30, 60, 90)." | ( Czasak, K; Jernajczyk, W; Musińska, I; Sobańska, A; Szatkowska, E; Wichniak, A; Wierzbicka, A, 2007) |
| "One of the most common treatments for insomnia is prescription sleep medications that help people fall asleep and remain asleep." | ( McKenzie, WS; Rosenberg, M, 2007) |
| "To provide an overview of insomnia, including identification and current treatments, as well as review the efficacy and safety of extended-release sleep medication." | ( Calamaro, C, 2008) |
| "Six months' therapy in adults with primary insomnia improved daytime functioning and health-related quality of life." | ( Curran, MP; Hair, PI; McCormack, PL, 2008) |
| "In patients with chronic insomnia, objectively assessed latency to persistent sleep (LPS) at week 1 was improved with oral ramelteon 8 mg administered 30 minutes before bedtime, compared with placebo, and this effect was maintained throughout the duration of 5-week and 6-month clinical studies." | ( Curran, MP; Simpson, D, 2008) |
| "Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication." | ( Andreescu, C; Buysse, DJ; Cyranowski, JM; Dombrovski, AY; Frank, E; Houck, PR; Mallinger, AG; Mulsant, BH; Thase, ME, 2008) |
| "However, until now treatment of insomnia has primarily targeted quantity of sleep." | ( Downie, S; Wade, A, 2008) |
| "Drugs prescribed for the treatment of insomnia can be either benzodiazepine hypnotics or the newer z-hypnotics, zopiclone and zolpidem." | ( Bramness, JG; Engeland, A; Furu, K; Hausken, AM; Skurtveit, S, 2009) |
| "Pharmacologic options for insomnia treatment include prescription hypnotics, such as gamma-amino butyric acid-receptor agonists, sedating antidepressants, over-the-counter antihistamines, melatonin-receptor agonists, and alternative therapies." | ( Bogan, RK, 2008) |
| "To describe the impact of current insomnia treatments on next-day performance." | ( Bogan, RK, 2008) |
| "Employed adults with chronic insomnia treated with zolpidem extended-release 12." | ( Erman, M; Guiraud, A; Joish, VN; Lerner, D, 2008) |
| "Forty patients with insomnia were divided into two groups and randomly received either the H7 or placebo treatments, in a double-blind protocol, for 20 nights." | ( Nordio, M; Romanelli, F, 2008) |
| "Cognitive behaviour therapy (CBT) of primary insomnia is frequently combined with various pharmacological treatments, including sedative antidepressants." | ( Brunovsky, M; Horacek, J; Höschl, C; Krajca, V; Matousek, M; Sos, P; Zavesicka, L, 2008) |
| "In adults with chronic insomnia, long-term ramelteon treatment consistently reduced sleep onset, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation." | ( Lehmann, R; Mayer, G; Partinen, M; Roth-Schechter, B; Staner, C; Wang-Weigand, S, 2009) |
| "Transient rebound insomnia was observed following discontinuation of treatment with zolpidem, but not gaboxadol." | ( Eglin, M; Hajak, G; Hedner, J; Loft, H; Lundahl, J; Lütolf, S; Stórustovu, SI, 2009) |
| "In patients with persistent insomnia, the addition of medication to CBT produced added benefits during acute therapy, but long-term outcome was optimized when medication is discontinued during maintenance CBT." | ( Baillargeon, L; Bastien, C; Guay, B; Ivers, H; Mérette, C; Morin, CM; Savard, J; Vallières, A, 2009) |
| "(1) Patients complaining of insomnia should first be treated with non-drug measures (information, advice)." | ( , 2008) |
| "Newer treatment options for insomnia include the non-benzodiazepine hypnotics zolpidem, zolpidem-controlled release, zaleplon, zopiclone, eszopiclone and the melatonin receptor agonist, ramelteon." | ( Zammit, G, 2009) |
| "Current treatment of insomnia with hypnotics, GABA(A) receptor modulators, induces various side effects, including cognitive impairment, motor disturbance, dependence, tolerance, hang-over, and rebound insomnia." | ( Miyamoto, M, 2009) |
| "The Athens Insomnia Scale (AIS) was used to evaluate the clinical therapeutic effects, while the treatment emergent symptom scale (TESS) was used to evaluate adverse reactions." | ( Deng, SP; Xia, CY; Zhu, PJ, 2009) |
| "Eszopiclone treats insomnia and cooccurring menopause-related symptoms." | ( Cohen, LS; Farrell, A; Joffe, H; Koukopoulos, A; Petrillo, L; Silver, M; Silver-Heilman, K; Viguera, A; Yu, G, 2010) |
| "Patients with DSM-IV-TR defined primary insomnia were asked to record a sleep diary one week prior to treatment, followed by 2 weeks of nightly treatment with either Quetiapine 25 mg or placebo." | ( Kiewyoo, J; Paholpak, S; Tassniyom, K; Tassniyom, S, 2010) |
| "The final sample (N=1273) reported that insomnia was a major problem in almost a third of their school-aged and adolescent patients and endorsed using medication to treat the insomnia in at least a quarter of these patients." | ( Kirchner, HL; Mindell, JA; Owens, JA; Rosen, CL, 2010) |
| "ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep." | ( Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB, 2010) |
| "Subjects meeting DSM-IV-TR criteria for primary insomnia were randomized to 12 weeks of nightly treatment with doxepin (DXP) 1 mg (n = 77) or 3 mg (n = 82), or placebo (PBO; n = 81)." | ( Durrence, HH; Jochelson, P; Krystal, AD; Ludington, E; Rogowski, R; Roth, T; Scharf, M, 2010) |
| "Cognitive-behavioral therapy targeting insomnia can effectively enhance the response to antidepressant medication." | ( Howland, RH, 2011) |
| "Significant improvements in insomnia were observed for eszopiclone cotherapy relative to placebo cotherapy (mean change from baseline on the ISI: -11." | ( Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A, 2011) |
| "To compare the therapeutic effects of insomnia accompanied with depressive disorders treated by acupuncture of relieving depression and regulating mind and oral administration of Trazodone." | ( Lai, XS; Luo, WZ; Zhang, QZ, 2010) |
| "In Japanese adults with chronic insomnia, ramelteon 8 mg significantly reduced patient-reported sleep latency, increased total sleep time and improved sleep quality after 1 week of treatment." | ( Hamamura, M; Kuwano, T; Nagata, H; Nishiyama, H; Uchimura, N; Uchiyama, M, 2011) |
| "Current pharmacological treatment of insomnia involves the use of sedative-hypnotic benzodiazepine and non-benzodiazepine drugs." | ( Brown, GM; Brzezinski, A; Cardinali, DP; Pandi-Perumal, SR; Spence, DW; Srinivasan, V, 2011) |
| "The nature and prevalence of insomnia are described in this review, along with the current pharmacological treatments for the disorder." | ( Lankford, DA, 2011) |
| "The Athens Insomnia Scale (AIS), Sheehan Disability Scale (SDS), and Clinical Global Impression scale (CGI) were completed at baseline, after each month of treatment and after the first week of run-out phase." | ( Jernajczyk, W; Wichniak, A; Wierzbicka, A, 2011) |
| "RIS-LAI-treated patients." | ( Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B, 2012) |
| "Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs." | ( Wichniak, A; Wierzbicka, A, 2011) |
| "Patients meeting DSM-IV-TR criteria for primary insomnia were randomized to 35 days of nightly treatment with DXP 3 mg (n=75), DXP 6 mg (n=73), or placebo (PBO; n=73), followed by 2 nights of single-blind PBO to evaluate discontinuation (DC) effects." | ( Durrence, HH; Jochelson, P; Krystal, AD; Lankford, A; Ludington, E; Rogowski, R; Roth, T, 2011) |
| "The MSLTs of insomniacs during treatment in study month 1 were correlated (r = 0." | ( Harris, E; Maan, R; Randall, S; Roehrs, TA; Roth, T, 2011) |
| "There are limited data on the impact of insomnia in response to acute treatment, which is particularly relevant with serotonin-selective reuptake inhibitors, given their tendency to worsen sleep architecture." | ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012) |
| "While adolescents reporting substantial insomnia were less likely to respond to antidepressant treatment than those without insomnia, children were more responsive to fluoxetine when they had insomnia." | ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012) |
| "Pharmacological treatment of insomnia include the use of benzodiazepine and non-benzodiazepine drugs like zolpidem, zaleplon, Zopiclone." | ( Brown, GM; Brzezinski, A; Othaman, Z; Prasad, A; Srinivasan, V; Zakaria, R, 2012) |
| "Optimal administration plan for insomniac patients to induce these characteristic sleep-modulating effects by ramelteon was discussed." | ( Mishima, K, 2012) |
| "In adults with primary insomnia, nightly zolpidem administration remained efficacious across 8 months of nightly use." | ( Randall, S; Roehrs, TA; Roth, T, 2012) |
| "Recently, it becomes evident that insomnia is a risk of developing cardiovascular diseases; therefore, treatment of insomnia is important for treatment of cardiovascular diseases." | ( Hiromasa, S, 2013) |
| "Currently approved treatments for insomnia primarily target γ-aminobutyric acid-A (GABA-A) receptor signalling and include benzodiazepines and GABA-A receptor modulators." | ( Renger, JJ; Winrow, CJ, 2014) |
| "In 3,455 MDD outpatients with insomnia after treatment, the reduction of sleep latency (P < 0." | ( Hao, W; Li, L; Li, Z; Wang, D, 2014) |
| "Fifty-four pregnant women with insomnia were randomly assigned to trazodone, diphenhydramine, or placebo treatment." | ( Emamian, F; Ghadami, MR; Khazaie, H; Knight, DC; Tahmasian, M, 2013) |
| "However, residual insomnia symptoms after treatment were strongly associated with elevated depressive symptoms assessed by the HAM-D after 4 months (β = 0." | ( Blumenthal, JA; Carney, RM; Combs, K; Craighead, WE; Freedland, K; Hoffman, B; Sherwood, A; Smith, PJ, 2014) |
| "The model of insomnia rats were established by PCPA intraperitoneal injection, after the modeling, all the therapeutic group were treated with corresponding drug for one week." | ( Chen, JF; Gao, JR; Ji, WB; Jiang, H, 2013) |
| "Cognitive behavioral therapy for insomnia (CBT-I) is well-validated in the western countries." | ( Hong, L; Huang, YY; Li, GX; Li, T; Lin, YN; Liu, YJ; Wang, F; Wang, WD; Yan, X; Zhao, Y, 2014) |
| "Recent data suggest that adding insomnia therapy to pain-targeted treatment should improve outcome; however, this has not been empirically tested in LBP or in any pain condition treated with a standardized pain medication regimen." | ( Goforth, HW; Krystal, AD; Preud'homme, XA, 2014) |
| "The addition of insomnia-specific therapy to a standardized naproxen pain regimen significantly improves sleep, pain, and depression in patients with chronic low back pain (LBP)." | ( Goforth, HW; Krystal, AD; Preud'homme, XA, 2014) |
| "In the comorbid insomnia (PSQI ≥6) subgroup, PRM treatment resulted in significant and clinically meaningful effects versus the placebo, in mean IADL (P=0." | ( Farmer, M; Frydman-Marom, A; Fund, N; Harari, G; Laudon, M; Nir, T; Wade, AG; Zisapel, N, 2014) |
| "Aside from treating insomnia, using zolpidem in the presence of SSRIs may have some unidentified therapeutic effects for depressed individuals." | ( Conn, NA; Jensen, JE; Licata, SC; Lukas, SE; Winer, JP, 2014) |
| "Forty insomniac postmenopausal women with no severe vasomotor symptoms and/or recognized hot flushes during sleep were randomized into 2 months' treatment with a 50-μg transdermal estradiol patch or placebo." | ( Chaikittisilpa, S; Jaimchariyatam, N; Jaisamrarn, U; Panyakhamlerd, K; Taechakraichana, N; Tansupswatdikul, P, 2015) |
| "Estrogen therapy in insomniac postmenopausal women without severe vasomotor symptoms and/or recognized hot flushes during sleep was not found to improve sleep efficiency during the study period." | ( Chaikittisilpa, S; Jaimchariyatam, N; Jaisamrarn, U; Panyakhamlerd, K; Taechakraichana, N; Tansupswatdikul, P, 2015) |
| "Its approval for the treatment of insomnia was based on three clinical trials that found it to be efficacious and relatively well tolerated." | ( Howland, RH, 2014) |
| "Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup." | ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "Those with pre-treatment insomnia were more likely to be female (69." | ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "To test if improvement of insomnia during treatment of chronic fatigue was associated with improved outcomes on 1) fatigue and 2) cortisol recovery span during a standardized stress exposure." | ( Borchgrevink, PC; Jacobsen, HB; Kallestad, H; Landrø, NI; Stiles, TC, 2015) |
| "The frequency of constipation and insomnia which were antiemetic treatment-related adverse events was similar between two groups, and no serious adverse events occurred." | ( Furukawa, N; Ito, F; Kanayama, S; Tanase, Y, 2015) |
| "It is approved for the treatment of insomnia characterized by sleep onset difficulties in the US and Japan, but not in Europe." | ( Bedini, A; Lucarini, S; Mor, M; Rivara, S; Spadoni, G, 2015) |
| "Therefore, insomnia and alcohol dependence might be best thought of as co-occurring disorders, each of which requires its own treatment." | ( Brower, KJ, 2015) |
| "Adults with primary insomnia were treated with esmirtazapine (3." | ( Ivgy-May, N; Krystal, A; Roth, T; Ruwe, F, 2015) |
| "Her delirium-like symptoms, including insomnia, visual hallucinations, and a long-term memory deficit, disappeared after cessation of oseltamivir and administration of benzodiazepine." | ( Hosokawa, M; Kashii, H; Kubota, M; Morimoto, K; Nagai, A; Nagaoka, K; Ogihara, T; Takahashi, Y, 2015) |
| "A total of 74 subjects with chronic Insomnia were treated with 10 mg zolpidem for 4 weeks." | ( Ader, R; Andalia, P; Barilla, H; Bootzin, R; Bremer, E; Gehrman, P; Grandner, M; Morales, K; Perlis, M; Thase, M; Whinnery, J; Zee, J, 2015) |
| "In adults with primary insomnia, nightly zolpidem administration showed no gender differences in acute or chronic efficacy or in next-day sleepiness." | ( Roehrs, TA; Roth, T, 2016) |
| "Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve insomnia in cancer patients, but less is known about its ability to impact fatigue." | ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "The primary endpoint was the Insomnia Severity Index after four weeks of treatment." | ( Bittencourt, LR; Braga, LR; Pinto, LR; Treptow, EC; Tufik, S, 2016) |
| "Based on the Insomnia Severity Index at the end of four weeks of treatment, eszopiclone demonstrated efficacy comparable to that of zopiclone in the treatment of insomnia, increasing total sleep time as well as sleep efficiency according to polysomnography." | ( Bittencourt, LR; Braga, LR; Pinto, LR; Treptow, EC; Tufik, S, 2016) |
| "Clonazepam (CNZ) is a drug used for insomnia treatment." | ( Contreras-González, N; Haro, R; Jiménez-Correa, U; Poblano, A; Téllez-Alanís, B, 2015) |
| "For the treatment of insomnia in older adults, eszopiclone may present a safer alternative to zolpidem, in terms of fall-related injuries." | ( Albrecht, JS; Park, Y; Tom, SE; Wickwire, EM, 2016) |
| "Unfortunately, however, pediatric insomnia most often remains unidentified and untreated." | ( Badin, E; Haddad, C; Shatkin, JP, 2016) |
| "This article focuses on insomnia and presents a treatment algorithm for managing insomnia in older adults, along with a representative clinical case." | ( Bramoweth, AD; Buysse, DJ; Gentili, A; Germain, A; Kochersberger, G; Renqvist, JG; Rodriguez, E; Rossi, MI; Weiner, DK, 2016) |
| "There was a trend for less insomnia in the agomelatine group versus MPH-treated group (4% vs." | ( Akhondzadeh, S; Khiabany, M; Kohi, A; Mohammadi, MR; Mohammadinejad, P; Salardini, E; Shahriari, M; Zeinoddini, A, 2016) |
| "Sleep disorders are treated using anti-insomnia drugs that target ionotropic and G protein-coupled receptors (GPCRs), including γ-aminobutyric acid (GABA) agonists, melatonin agonists, and orexin receptor antagonists." | ( Sakurai, T; Sasaoka, T; Tsuneki, H, 2016) |
| "Participants were 160 individuals with chronic insomnia who received CBT alone or CBT plus medication (zolpidem) for an initial six-week therapy, followed by an extended six-month therapy." | ( Beaulieu-Bonneau, S; Bélanger, L; Guay, B; Ivers, H; Mérette, C; Morin, CM; Sánchez Ortuño, M; Savard, J; Vallières, A, 2016) |
| "These data show that some insomniacs are hyperaroused with high MSLT/NE levels and, compared to low MSLT/NE insomniacs, they increase the number of capsules (zolpidem and placebo) self-administered on months four and 12 relative to Month one." | ( Roehrs, TA; Roth, T, 2016) |
| "There was an intermittent reduction in insomnia in both active treatment arms versus PBO, with o-CEE being more effective than PBO at 36 and 48 months (P = 0." | ( Allshouse, A; Black, DM; Brinton, EA; Budoff, MJ; Cedars, MI; Dowling, NM; Dunn, M; Gleason, CE; Harman, SM; Hodis, HN; Isaac, B; Lobo, RA; Magnani, M; Manson, JE; Miller, VM; Naftolin, F; Neal-Perry, G; Pal, L; Santoro, N; Taylor, HS; Wharton, W; Wolff, E; Zepeda, V, 2017) |
| "Patients with comorbid depression and insomnia who experienced the first onset of both disorders in childhood are less responsive to the treatments offered herein than are those with adult onsets of these comorbid disorders." | ( Buysse, DJ; Edinger, JD; Fairholme, CP; Gehrman, P; Krystal, AD; Luther, J; Manber, R; Thase, ME; Wisniewski, S, 2017) |
| "Selected PSs (insomnia, anxiety, depression, and suicidality) occurring in HIV-positive patients during DTG treatment across 5 randomized clinical trials (3 double-blind), in the Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort, and among cases spontaneously reported to ViiV Healthcare were analyzed." | ( Aboud, M; Curtis, L; Fettiplace, A; Fusco, J; Givens, N; Hsu, R; Puccini, S; Quercia, R; Stainsby, C; Vannappagari, V; Winston, A, 2017) |
| "Behavioral therapies for insomnia include the following: sleep hygiene, cognitive behavioral therapy for insomnia, multicomponent behavioral therapy or brief behavioral therapy for insomnia, relaxation strategies, stimulus control, and sleep restriction." | ( Almoznino, G; Benoliel, R; Haviv, Y; Sharav, Y, 2017) |
| "QOL and insomnia severity were assessed before, during the intervention, at post-intervention, and 3 months later by Functional Assessment of Cancer Therapy-General and Insomnia Severity Index, respectively." | ( Garland, SN; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Peoples, AR; Peppone, LJ; Perlis, ML; Roscoe, JA; Ryan, JL; Savard, J, 2017) |
| "Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia." | ( Babson, KA; Morabito, D; Sottile, J, 2017) |
| "The results suggest that CBT for insomnia, when delivered alone or in combination with medication, produce durable sleep improvements up to two years after completion of treatment." | ( Beaulieu-Bonneau, S; Guay, B; Ivers, H; Morin, CM, 2017) |
| "The societal cost of insomnia is on the rise, while long-term use of current drug treatments can involve adverse effects." | ( Cho, JH; Jung, IC; Kim, AR; Kim, BK; Kim, HJ; Kim, JE; Kim, JH; Kim, MK; Kim, SP; Kwon, OJ; Park, HJ; Seo, BN, 2017) |
| "Treatment for insomnia with melatonin (MT) in children and adolescents aged 0-17 years has doubled since 2011." | ( Berring-Uldum, A; Debes, NMM; Holst, H; Pedersen, CR, 2018) |
| "Study subjects were patients with insomnia (42 cases), who were divided into a ramelteon group (22 cases; administered 8 mg/day of ramelteon before sleep in addition to BZ) and a control group (20 cases; continually administered only BZs), with a mean disease duration of 11." | ( Abe, H; Araki, R; Funahashi, H; Ishida, Y; Naono-Nagatomo, K; Takeda, R; Taniguchi, H, 2018) |
| "Both insomnia and its treatment can lead to the development of delirium in older adults." | ( Isik, AT; Kalan, U; Soysal, P, 2018) |
| "The presence of insomnia in the context of depression is linked to a number of poor outcomes including reduced treatment response, increased likelihood of relapse, and greater functional impairment." | ( Bertulis, K; Boland, EM; Gehrman, PR; Leong, SH; Thase, ME, 2019) |
| "Cognitive behavioral therapy for insomnia (CBT-I) and eszopiclone are 2 commonly prescribed strategies for insomnia." | ( Hu, W; Liu, Y; Mao, J; Ren, W; Su, J; Tang, G; Wang, J; Yu, Z; Zhang, Y, 2018) |
| "Both groups received treatment for insomnia in the form of either zolpidem 5 mg for 7 days or sleep hygiene counseling." | ( Asok, A; Cc, A; K, P; P, UD; Sreekumar, S; Tk, R, 2019) |
| "Patients with insomnia (n = 70) received 4 weeks' usual care with an FDA-approved hypnotic agent; patients with depression (n = 651) received 8 weeks' active or experimental therapy." | ( Ball, W; Cai, B; DeMuro, C; Morrison, MF; Snyder, E, 2018) |
| "We examined trends in insomnia diagnosis and treatment among Medicare beneficiaries over an eight-year period." | ( Albrecht, JS; Scharf, SM; Tom, SE; Vadlamani, A; Wickwire, EM, 2019) |
| "Results from this study on treatment of insomnia in advanced cancer will contribute to clinical decision-making and improve the treatment of sleep disturbance in this patient cohort." | ( Engstrøm, M; Fayers, P; Hjermstad, MJ; Jakobsen, G; Kaasa, S; Klepstad, P; Paulsen, Ø; Raj, SX; Sjue, K; Thronæs, M, 2018) |
| "Among 84 patients who experienced insomnia during PSG and required hypnotics (the insomnia group; treated with suvorexant), 44 (52." | ( Kinoshita, T; Koshikawa, K; Matsumura, T; Nagashima, K; Sakao, S; Tatsumi, K; Terada, J; Yahaba, M; Yoshimura, C, 2019) |
| "Pharmacological treatments for insomnia include benzodiazepines (BZs) and the non-BZ 'Z-drugs' (zolpidem, zaleplon, eszopiclone, zopiclone), which are amongst the most widely prescribed medications." | ( Moniri, NH, 2019) |
| "Psychopharmacotherapy for insomnia in mental disorders is an important aspect of patient supervision." | ( Petelin, DS; Poluektov, MG; Volel, BA, 2019) |
| "To reveal the influence of insomnia on the levels of the neurotransmitters including serotonin (5-HT), glutamic acid (Glu), γ-aminobutyric acid (GABA), noradrenaline (NE) and dopamine (DA), and to study the role of ZSS aqueous extract in the treatment of insomnia, an UPLC-ESI- MS/MS method was developed and validated for simultaneous determination of five neurotransmitters in the rat brain." | ( DU, CH; DU, HZ; Li, AP; Li, Q; Pei, XP; Qin, XM; Shen, CX; Yan, Y, 2019) |
| "Reducing Suicidal Ideation Through Insomnia Treatment was an 8-week three-site double-blind placebo-controlled parallel-group randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in conjunction with an open-label selective serotonin reuptake inhibitor." | ( Benca, RM; Case, D; Krystal, AD; McCall, WV; McCloud, L; Newman, JC; Phillips, M; Rosenquist, PB; Rumble, ME; Szabo, ST; Youssef, NA, 2019) |
| "Treatment of insomnia should ideally improve the sleep profile while minimally affecting mnemonic function, yet many hypnotic drugs (e." | ( Gamble, MC; Katsuki, F; McCoy, JG; McKenna, JT; Strecker, RE, 2020) |
| "We reviewed age, sex, insomnia etiology, years of evolution, number of previously used drugs, and the results of perampanel for insomnia after 3 months of treatment in the exposed cohort, measured by the improvement of 3 or more points in the ISI and Pittsburgh scales, as well as the average of hours of sleep gained." | ( Abenza-Abildúa, MJ; Andreu-Vazquez, C; Suárez-Gisbert, E; Thuissard-Vasallo, IJ, 2020) |
| "A total of 949 participants with insomnia (age ≥18 years) were randomized, received treatment with an oral dose of placebo or LEM (5 mg [LEM5] or 10 mg [LEM10]) and were analyzed." | ( Filippov, G; Inoue, Y; Ishikawa, K; Kärppä, M; Kubota, N; Moline, M; Perdomo, C; Pinner, K; Yardley, J; Zammit, G, 2020) |
| "Whether insomnia with objective short sleep duration responds better to pharmacological treatment compared to CBT-I has not been examined." | ( Basta, M; Bixler, EO; Fernandez-Mendoza, J; Krishnamurthy, VB; Puzino, K; Vgontzas, AN, 2020) |
| "Recent advancements in the treatment of insomnia includes agents with novel mechanisms, new indications, and new dosage forms." | ( Earl, DC; Van Tyle, KM, 2020) |
| "The cognitive behavioral therapy for insomnia (CBT-I) can be recommend to treat insomnia during euthymic phases." | ( Geoffroy, PA; Palagini, L, 2021) |
| "There was no evidence of rebound insomnia or withdrawal in either lemborexant group following treatment discontinuation." | ( Filippov, G; Inoue, Y; Ishikawa, K; Kärppä, M; Kubota, N; Moline, M; Perdomo, C; Pinner, K; Yardley, J, 2021) |
| "Because some pharmacotherapy for insomnia causes respiratory depression, this study assessed the effects of lemborexant treatment on respiratory safety parameters." | ( Bsharat, M; Cheng, JY; Filippov, G; Hall, N; Moline, M; Zammit, GK, 2021) |
| "Although the application of an insomnia medication for treating NE seems paradoxical, suvorexant reduced the frequency of NE in patients with severe intractable NE." | ( Matsumoto, T, 2021) |
| "All had insomnia (Pittsburgh Sleep Quality Index (PSQI) ≥ 5), not treated with any medications, for at least three months before enrollment." | ( Kang, HT; Kim, Y; Lee, DC, 2021) |
| "Lemborexant can be recommended to treat insomnia disorder when pharmacological treatment is warranted." | ( Waters, K, 2022) |
| "In this study, the standardization of insomnia treatment was evaluated by pharmacoeconomics." | ( Akiyama, M; Ishida, H; Kitahara, T; Kouda, K; Matsunaga, K; Saisyo, A; Takasago, M; Takasaki, A; Wakabayashi, K, 2021) |
| "Pharmacotherapy for insomnia consists of different types of drugs." | ( Chao, D; Chun, W; Dongliang, Z; Jia, L; Qi, H; Zhenmei, L, 2021) |
| "There is evidence that treating insomnia may improve not only sleep, but depression and metabolic function, as well." | ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| "Adults (18-85 years) with insomnia disorder (Diagnostic and Statistical Manual of Mental Disorders-5) who ask their general practitioner (GP) for sleep medication when non-pharmacological treatment is deemed not effective, are eligible." | ( Bakker, MH; Hugtenburg, JG; Slottje, P; van der Horst, HE; van Straten, A, 2021) |
| "In the setting of Alzheimer's disease, insomnia is an even more complicated issue, with a higher overall prevalence than in the general population, greater complexity of contributing etiologies, and differences in diagnosis (at times based on caregiver observation of sleep disruption rather than subjective complaints by the individual with the disorder), and requiring more discretion in terms of treatment, particularly in regard to adverse effect profile concerns." | ( Bliwise, DL; Roland, JP, 2021) |
| "However, when using zolpidem to treat insomnia, its effect on sleep structure should be considered." | ( Cai, Y; Hong, Z; Pan, J; Xiang, T, 2021) |
| "It is common to provide insomnia patients a second treatment when the initial treatment fails, but little is known about optimal treatment sequences for different patient types." | ( Beaulieu-Bonneau, S; Bélanger, L; Edinger, JD; Guay, B; Ivers, H; Morin, CM; Simmons, B, 2022) |
| "In the caffeine-induced insomnia model, the administration of a Saaz-Saphir mixture increased the sleep time compared to Saaz or Saphir administration alone, which was attributed to the increase in NREM sleep time by the δ-wave increase." | ( Ahn, Y; Cho, HJ; Jo, K; Kwak, WK; Min, B; Suh, HJ, 2021) |
| "Cognitive behavioral therapy for insomnia (CBT-I) is first choice treatment and effective for people with insomnia and comorbid long-term medical conditions." | ( Boss, HM; Braamse, AMJ; Knoop, H; Pot, I; Rauwerda, NL; Rikkert, ME; Timmerhuis, TPJ; van Straten, A; Zondervan, A, 2021) |
| "Cognitive-behavioral therapy for insomnia is indicated to treat chronic insomnia in neurocognitive disorders." | ( Carrier, J; Dang-Vu, TT; Moderie, C, 2022) |
| "In the treatment of insomnia, trazodone is less effective than hypnotics in the treatment of sleep onset insomnia (i." | ( Jarema, M; Wichniak, A; Wierzbicka, AE, 2021) |
| "Relative to matched controls, the insomnia-treated cohort showed higher risk of falls with greater HCRU and costs." | ( Amari, DT; Atkins, N; Frech, FH; Gor, D; Juday, TR; Wang, W; Wickwire, EM, 2022) |
| "Clonidine is better than zopiclone for insomnia treatment in chronic pain patients." | ( Bamgbade, DO; Bamgbade, OA; Fadire, A; Mumporeze, L; Murphy-Akpieyi, O; Soni, NK; Tai-Osagbemi, J, 2022) |
| "Evaluate changes in insomnia severity in subjects with moderate to severe insomnia (Insomnia Severity Index [ISI] score ≥15) treated for 12 months nightly with lemborexant." | ( Atkins, N; Malhotra, M; Moline, M; Morin, CM; Pappadopulos, E; Perdomo, C; Pinner, K; Rosenberg, R; Roth, T; Yardley, J, 2022) |
| "Further study of the impact of newer insomnia treatments on patient outcomes in depression and comorbid insomnia is warranted." | ( Amari, DT; Frech, F; Gor, D; Juday, TR; Malhotra, M; Wickwire, EM, 2022) |
| "The usual pharmacologic treatment for insomnia has been benzodiazepines and barbiturates." | ( Callede, N; Casettari, L; Goole, J; Loosveldt, N; Masciotti, T, 2022) |
| "Cognitive behavioural therapy for insomnia is an effective treatment to improve sleep for people with chronic pain, but further high-quality primary research is required to explore combined CBT content that will ensure additional improvements to pain, quality of life and psychological health and longer-term maintenance of benefits." | ( Beswick, A; Dennis, J; Gooberman-Hill, R; Whale, K; Wylde, V, 2022) |
| "While some research has found that insomnia heightens falls, health care resource utilization (HCRU) and costs, the impact of insomnia treatments on fall risk, mortality, HCRU and costs in the elderly population, which could be of substantial interest to payers, has not been fully elucidated." | ( Amari, DT; Atkins, N; Frech, FH; Juday, T; Wang, W; Wickwire, EM; Wu, Z, 2022) |
| "Medicare beneficiaries treated for insomnia receiving zolpidem extended-release, zolpidem immediate-release, trazodone, or benzodiazepines were matched with non-sleep disordered controls." | ( Amari, DT; Atkins, N; Frech, FH; Juday, T; Wang, W; Wickwire, EM; Wu, Z, 2022) |
| "Individuals receiving insomnia treatment had an increased risk of falls and mortality and higher HCRU and costs compared with matched beneficiaries without sleep disorders." | ( Amari, DT; Atkins, N; Frech, FH; Juday, T; Wang, W; Wickwire, EM; Wu, Z, 2022) |
| "Several risk factors for insomnia in cancer patients have been recognized, including chronic pain and treatment with opioid." | ( Akui, C; Hirose, M; Kimura, T, 2022) |
| "Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a phase III, 12-month, global, multicenter, randomized, double-blind, parallel-group study who completed 12 or 6 months of active treatment and follow-up period." | ( Inabe, K; Kuriyama, K; Moline, M; Nishi, Y; Pinner, K; Suzuki, M; Takaesu, Y, 2023) |
| "Sixty patients with insomnia in massage clinic and ward were randomly divided into treatment group A (30 cases) and treatment group B (30 cases)." | ( Guan, R; Li, J; Liu, Z; Pan, L; Shi, Q; Yu, Z, 2023) |
| "We performed a meta-analysis of insomnia in randomized controlled trials (RCTs) of patients with schizophrenia treated with clozapine." | ( McCall, WV; McEvoy, JP; Miller, BJ, 2023) |
| "Although craving is associated with insomnia, treatment with quetiapine may improve insomnia but not craving in patients with co-occurring AUD and insomnia." | ( Chakravorty, S; Kampman, KM; Krouse, RA; Morales, KH, 2023) |
| "From an acute insomnia treatment perspective, priorities include testing large-scale online behavioural interventions; examining if reducing the impact of stress is effective and, finally, assessing whether "sleep vaccination" can maintain good sleep health by preventing the occurrence of acute insomnia, by preventing the transition from acute insomnia to insomnia disorder." | ( Altena, E; Elder, GJ; Ellis, JG; Palagini, L, 2023) |
| "Chronic insomnia disorder is one of the most common problems in postmenopausal women, exacerbated by underdiagnosis and improper treatment." | ( Sophonsritsuk, A; Thongchumnum, W; Vallibhakara, O; Vallibhakara, SA, 2023) |
| "This study investigated the course of insomnia symptoms during the acute treatment of major depressive disorder (MDD) using a secondary analysis of data from MDD patients (N = 180) who were treated with open-label escitalopram (10-20 mg/day) for 8-weeks." | ( Bhat, V; Dama, M; Demchenko, I; Frey, BN; Kennedy, SH; Lam, RW; Lou, W; Milev, RV; Parikh, SV; Ravindran, AV; Rotzinger, S; Tassone, VK; Wu, M, 2023) |
| "The treatment of insomnia, which is the most common sleep disorder, includes drug and behavioral treatment, but each treatment measure has its limitations." | ( Gao, X; Huang, Y; Li, J; Li, X; Li, Y; Liu, S; Wang, X; Xu, S; Zeng, Q, 2023) |
| "A total of 400 chronic insomnia patients will be allocated 1:1 to the intervention group (treatment with oral NMN 320 mg/day) or control group (treatment with oral placebo)." | ( Gao, X; Huang, Y; Li, J; Li, X; Li, Y; Liu, S; Wang, X; Xu, S; Zeng, Q, 2023) |
| "The key pathways in the treatment of insomnia with rosemary hydrosol were analyzed by molecular docking, open field assay, ELISA, western-Blot, Rt-PCR, and immunohistochemical assay." | ( Deng, K; Guo, D; Guo, J; Guo, Q; Li, H; Li, J; Li, T; Liu, D; Shi, Y; Sun, J; Tang, T; Wang, F; Wang, W; Wang, Y; Wu, Z; Yang, K; Yang, M; Zhang, X; Zou, J, 2024) |
| "Drugs commonly used in treating insomnia, such as melatonin, benzodiazepines, niaprazine, and antihistamines, are often either ineffective or associated with adverse effects, requiring new therapeutic perspectives." | ( Barbi, E; De Zen, L; Divisic, A; Molinaro, G; Solidoro, S, 2023) |
| "Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders." | ( Shaha, DP, 2023) |
| "These data suggest that even when insomnia symptoms have improved over time with placebo treatment, additional and sustained clinical gains in sleep outcomes are possible with active treatment using lemborexant." | ( Inoue, Y; Kubota, N; Moline, M; Perdomo, C; Perlis, ML; Pinner, K; Yardley, J, 2023) |
| "Cognitive impairment and insomnia are common complications for stroke patients, and often coexist without effective therapy." | ( Luo, F; Pan, G; Sui, S; Zhang, Y; Zhu, M, 2023) |